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The immunologic parameters of 23 patients with ery-
thema multiforme who were seen by us (17 patients) or 
who had biopsies sent for immunofluorescence testing 
(6 cases) are reviewed. Biopsy specimens were sectioned 
and tested with labeled antisera to human IgG, IgA, IgM, 
C3 and fibrin. Fourteen biopsies showed IgM deposits in 
the superficial blood vessels, 13 demonstrated C3, 15 
showed fibrin deposition, and 1 biopsy showed IgA dep-
osition. All biopsies were negative for IgG. Eight serum 
samples tested by indirect IF were negative for skin-
reactive antibodies. In addition to IF testing, serum sam-
ples from 20 patients were tested for circulating immune 
complexes with a Clq binding radioassay and a mono-
clonal rheumatoid factor (mRF) inhibition assay. Im-
mune complexes were not detected by the Clq binding 
assay, but 6 of 20 serum samples demonstrated low to 
moderate levels of immune complexes by the mRF inhi-
bition assay. By sucrose density gradient ultracentrifu-
gation the mRF-reactive material in one serum sample 
sedimented in high molecular weight fractions and also 
demonstrated anticomplementary activity. These find-
ings suggest that immune complex formation and sub-
sequent deposition in the cutaneous microvasculature 
may play a role in the pathogenesis of erythema multi-
forme. 
Erythema multiforme (EM) is a hypersensitivity reaction 
associated with disease states and sensitizers. These include all 
forms of infection, drugs, malignant disease, physical agents, x-
ray therapy, pregnancy and connective tissue diseases [1]. The 
etiology, however, is seldom found. Kazmierowski and Wuepper 
[2] recently reported the presence of C3 alone or with IgM and 
fibrin deposition in cutaneous blood vessels in 13 patients with 
EM. We wish to report our findings in 2.3 patients with EM 
who had biopsies performed for direct IF. We additionally 
examined sera from 20 of these patients for evidence of circu-
lating immune complexes by the Clq binding assay and a mRF 
inhibition assay. 
MATERIALS AND METHODS 
Patient Population 
Seventeen of the patients with EM were seen and evaluated by us 
personally. All patients presented with erythematous, urticarial or 
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Abbreviations: 
Agg lgG: heat aggregated lgG 
Clq BA: Clq binding activity 
EM: erythema multiforme 
IF: immunofluorescence 
mRF: monoclonal rheumatoid factor 
PEG: polyethylene glycol 
SDGU: sucrose density gradient ultracentrifugation 
target lesions in areas typical for EM. Histopathological examination 
was performed in 5 cases and was interpreted as consistent with EM. 
The patients who had biopsies sent for IF testing had EM as diagnosed 
by their dermatologists; serum samples were forwarded once the diag-
nosis was established. 
Reagents 
Reagents used in this study included: Sepharose 6B, Sephadex G-25 
and Sephadex G-200 (Pharmacia Fine Chemicals, Uppsala, Sweden); 
antibodies to lgG, lgM, IgA, C3 and fibrin (Meloy Laboratories, Inc., 
Springfield, Va., U.S.A.); IgG Cohn fraction II (Research Products 
Division, Miles Laboratories, Inc., Elkhart, Ind., U.S.A.); disodium 
ethylenediaminetetraacetate (EDTA) , ACS certified sucrose (Fisher 
Scientific Company, Pittsburgh, Pa., U.S.A.); CnBr (Eastman Kodak 
Company, Rochester, N.Y., U.S.A.) ; Polyethylene glycol6000, agarose, 
lactoperoxidase (Sigma Chemical Company, St. Louis, MO, U.S.A.); 
av icel microcrystalline cellulose (Brinkman Instruments, Inc., West-
bury, N.Y., U.S.A.); DNA and DNase I, (Worthington Biochemical 
Corporation, Freehold, NJ, U.S.A.) and 125I (New England Nuclear, 
Boston, Mass., U.S.A.). 
Immunofluorescence 
Biopsies obtained for direct IF studies were either quick frozen in 
liquid nitrogen (17 specimens) or shipped in holding solu tion (6 biop-
sies) . Biopsy specimens were processed within 1 week. Direct IF was 
performed by previously described methods [13] using monospecific 
antisera to lgG, IgA, lgM, C3 and fibrin. All antisera were checked for 
specificity and activity using standard double immunodiffusion and 
immunoelectrophoresis. Dilutions varied but conformed to om previ-
ously determined standards [4). In addition, serum samples from 8 
patients were tested by indirect IF staining by previously described 
methods [3,4] using monkey esophageal tissue as substrate. 
Clq Binding A ssay 
The Clq binding assay was performed by the method of Nydegger et 
al [5], with modifications by Tappeiner et al [6] and Zubler et a l [7]. 
C1q was isolated from fresh human serum by the method of Yonamasu 
and Stroud [8], and labeled with m.I in a lactoperoxidase-catalyzed 
reaction [9]. lgG (25 mg/ ml) was heated at 63°C for 12 min and 
separated by gel filtration on Sephamse 6B in 0.1 M Tris-HCL, 0.2 M 
NaCI, pH 8.5 [6). Protein eluting in the exclusion volume was used as 
heat aggregated (Agg) IgG. 
To assay C1q binding activity (C1qBA), 0.2 ml aliquots of serum 
sample were diluted in 0.2 ml of 0.26 M EDTA, pH 7.5. To each tube, 
0.5 ml of a 5 f.Lg/ml solu tion of 1251-C1q was added. After incubation, 3 
ml of a solution of polyethylene glycol (PEG) 6000 were added to make 
a final concentration of 1.5% PEG. The tubes were incubated at 4°C, 
centrifuged, the supernates discarded, and the remaining reactivity 
measured in a gamma scintillation spectrometer (Packard Instrument 
Company, Downers Grove, Ill. , U.S.A.) and calculated as percent of the 
total activity added. Results were compared to binding of known 
concentrations (5-1000 !lg Agg IgG Eq/ml). Normal levels of ClqBA 
were less than 5 f.Lg Agg IgG Eq/ml. 
mRF Inhibition Assay 
A radioassay utilizing mRF was performed by the method described 
by Luthra et a l [10]. In this solid-phase mRF inhibition assay, mRF 
was separated from the serum of a patient with macroglobulinemia 
which had been dialyzed against 0.1 M glycine HCL, pH 3.0 buffer for 
12 hT at 4 oc and applied to a Sephadex G-200 column in that buffer. 
The exclusion protein peak was conjugated with CnBr to microcrystal-
line cellulose beads. Agg IgG was applied to a sucrose density gradient, 
and aggregates greater than 25S were radiolabeled with '2"I [9]. Serum 
samples (0.5 dilution) , 0.5 ml 12''1 Agg lgG dilution (0.4 f.Lg/mll and 0.5 
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ml mRF-cellulose dilution were incubated in tubes, centrifuged, washed 
with buffer, then counted in a gamma scin t illation spectrometer. Re-
su.l ts were compared to a curve of Agg IgG (0.3-4 J.Lg/ ml) in normal 
human serum and expressed as J.Lg Agg IgG Eq/ml, as described above. 
Levels greater than 5 J.Lg Agg IgG Eq/ml were considered a bnormal. 
Sucrose Density Gradient Ultracentrifugation 
Sera (0.5 ml) from 3 patients were layered over a 5-40% sucrose 
gradient in Beckman polyallomer tubes. They were centrifuged at 
217,5000 g for 15 hr at 4 oc in a Beckman L5-50 preparative ultracen-
trifuge with a SW-40TI ro tor. Following centrifugation, the gradient 
tubes were punctured, a nd 14 fractions (approximately 0.65 ml each) 
were collected from the bottom. All fractions were then tested fo r 
protein content (0 D 280), immunoglobulin content (moleculru· weight 
markers), a nd for reactivity with Clq and mRF. Anticomplementary 
activity was also assayed by methods previously described (11]. 
RESULTS 
In this study, 20 of 23 patients demonstrated (singly or in 
combination) IgM, IgA, C3 or fibrin deposition in dermal blood 
vessel walls (Table I) . Fourteen biopsies demonstrated IgM in 
dermal blood vessels. Thirteen biopsies demonstrated C3 (Fig 
1), and 15 specimens were positive for fibrin (Table). One biopsy 
with blood vessel deposition of IgM and fibrin also demon-
strated deposition of IgA. Interestingly, all 23 biopsies were 
negative for IgG deposition. One patient demonstrated dermal-
S umma!)' of direct immunofluorescence of shin lesions from patients 
with erythema multiforme" 
Antiserum 
IgM, C3 and fibrin 
IgM 
C3 
Fibrin 
IgA 
IgG 
No. positive'' 
20 
14 
13 
15 
1 
0 
"Twenty-thTee patients were tested. 
Percent positive 
87 
61 
58 
65 
4 
0 
" Two biopsies showed deposit ion of C3 or fibrin at the basement 
membrane. 
FIG 1. Direct immunofluorescence of an early erythema mult iforme 
lesion with a la beled antiserum to human C3. Deposit ion of C3 in the 
superficial cutaneous blood vessels (arrows) is evident (reduced fTom 
X 400) . 
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FIG 2. Scattergram demonstrating mRF and Clq binding activity in 
serum samples of patients with erythema mul tiforme. Hatched areas 
indicate normal levels (less t ha n 5 J.Lg Agg IgG Eq/ ml). 
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FIG 3. Sucrose density gradient ultracentrifugation of serum fTom a 
patient with erythema multiforme. Protein content is shown 
(e----el with IgM (19S) and IgG (7S) markers. Anticomplementary 
activity (+) was detected in fractions 4 and 6. mRF reactive fractions 
are indicated by a brohen line. IgG was also detected in these same 
heavy fractions. (Collection of fractions is from the bottom of the 
tubes). 
epidermal deposition of fibrin, in addition to blood vessel C3 
and fibrin . Another biopsy showed granular C3 at the dermal-
epidermal junction. Another patient with severe recurrent EM 
failed, however, to demonstrate vessel IF in 2 biopsy specimens 
obtained during acute exacerbations at approximately 1-yr in-
tervals. Indirect IF for skin and mucosa-reactive antibodies was 
negative in 8 patients tested. 
Serum samples from 20 patients were tested by mRF inhibi-
tion and C1q binding radioassays. All 20 EM sera examined 
were negative by the C1q binding assay (Fig 2). Six of 20 sera, 
however, were positive by the mRF inhibition assay. Levels of 
mRF -reactive material ranged from 12 to 92 /Lg Agg IgG Eq/ 
ml. One patient had a level of 27 /Lg Agg IgG Eq/ml during the 
initial episode of EM. During a second attack, however, a 
normal level (less than 5 /Lg Agg IgG Eq/ ml) was found. 
Three of the mRF-reactive sera were fractionated by SDGU. 
In one of the serum specimens fractionated, high molecular 
weight mRF-reactive material was detected (Fig 3). Interest-
ingly, this activity sedimented in fractions greater than 19S. 
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Despite the lack of reactivity with C1q, these fractions also 
showed anticomplementary activity. The complement pathway 
(classical or alternative) activated by the mRF-reactive mate-
rial, however, was not determined in these studies. 
DISCUSSION 
By the direct IF method, 87% of biopsies from patients with 
active EM demonstrated blood vessel deposition of either IgM, 
C3 or fibrin. In addition, simultaneous deposition of all 3 
proteins was noted in 7 of the patients (30%). Our findings 
therefore are similar to and confirm studies by Kazmierowski 
and Wuepper [2] who found concomitant IgM, C3 and fibrin in 
the superficial dermal microvasculature in 43% of their patients. 
A total of94% of their EM biopsies demonstrated positive blood 
vessel IF, a figure which is also similar to that obtained in our 
laboratory (87%). · 
Of the 3 patients who failed to demonstrate dermal blood 
vessel IF, one had C3 deposits at the dermal-epidermal junction. 
Surprisingly, this patient and another with negative IF were 
the two most severely affected individuals, requiring frequent 
oral corticosteroid therapy. 
Based on the above positive findings, serum samples were 
also tested for the presence of circulating immune complexes. 
Although immune complex-like material was not detected by 
the C1q binding assay, 6 of 20 serum samples revealed mild to 
moderate le~els when tested by the mRF inhibition assay (Fig 
2). All 6 of these sera were from patients with positive vessel 
IF. 
The presence of immune complex-like substances in EM 
blister fluid and sera have been reported by others. Safai, Good 
and Day [2] demonstrated C1q-reactive material in blister fluids 
of 2 patients, although similar material was not detected in the 
serum. They also reported low levels of total hemolytic com-
plement and individual complement components in blister fluid. 
In contrast to our studies, Swinehart et al [13] and Huff et al 
[14] reported that 11 of 26 EM sera were immune complex-
positive by the C1q binding radioassay. These conflicting re-
sults, however, may reflect differences in serum sampling or an 
increased sensitivity of their C1q binding assay . For example, 
a higher concentration of PEG (4%) is used to precipitate the 
complexes by their method, compa1·ed to 1.5% PEG in our C1q 
binding assay. In addition, over 50% of their patients demon-
strated cryoprecipitates in serum samples. 
In a recently completed study of patients with leukocytoclas-
tic vasculitis [11], 2 distinct patterns were observed when serum 
samples were fractionated by SDGU. Serum samples which 
were positive by both the Clq binding and mRF inhibition 
radioassays consistently demonstrated high molecular weight 
(19S or greater) immune complex-like material. C1q binding-
negative, mRF-positive sera, however, demonstrated immune 
complexes of intermediate size (approximately 12-14S) in the 
SDGU separations. In EM, however, one C1q-negative, mRF-
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positive serum sample showed reactivity in heavy molecular 
weight fractions (19S or greater) following SDGU separation. 
These same fractions also demonstrated anticomplementary 
activity, a phenomenon which is being investigated further. 
At present, it is not known whether the mRF-reactive mate-
rial, presumably due to the presence of immune complexes, is 
epiphenomenal or pathogenic in EM. The nature of the anti-
gens, immunoglobulin composition and pathway of complement 
activation must also be determined. Such studies, now in prog-
ress, may further implicate immune complexes in the pathogen-
esis of this disease. 
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